Aerie Pharmaceuticals Inc. (AERI) is priced at $11.55 after the most recent trading session. At the very opening of the session, the stock price was $11.27 and reached a high price of $11.90, prior to closing the session it reached the value of $11.12. The stock touched a low price of $11.18.
Recently in News on September 15, 2020, Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%. Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that its sterile fill production facility in Athlone, Ireland has received approval from the U.S. Food and Drug Administration (FDA) for production of Rhopressa® (netarsudil ophthalmic solution) 0.02% for commercial distribution in the United States. This approval comes following the FDA review of the New Drug Application Prior Approval Supplement (PAS), which added the Athlone production facility as a drug product manufacturer for Rhopressa®. You can read further details here
Aerie Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $26.26 on 01/09/20, with the lowest value was $10.22 for the same time period, recorded on 08/28/20.
Aerie Pharmaceuticals Inc. (AERI) full year performance was -51.55%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Aerie Pharmaceuticals Inc. shares are logging -56.02% during the 52-week period from high price, and 13.01% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $10.22 and $26.26.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1237811 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Aerie Pharmaceuticals Inc. (AERI) recorded performance in the market was -52.21%, having the revenues showcasing -23.10% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 556.25M, as it employees total of 380 workers.
Specialists analysis on Aerie Pharmaceuticals Inc. (AERI)
During the last month, 0 analysts gave the Aerie Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 13.59, with a change in the price was noted -2.46. In a similar fashion, Aerie Pharmaceuticals Inc. posted a movement of -17.56% for the period of last 100 days, recording 848,563 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AERI is recording 2.22 at the time of this writing. In addition, long term Debt to Equity ratio is set at 2.22.
Trends and Technical analysis: Aerie Pharmaceuticals Inc. (AERI)
Raw Stochastic average of Aerie Pharmaceuticals Inc. in the period of last 50 days is set at 33.67%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 50.96%. In the last 20 days, the company’s Stochastic %K was 30.41% and its Stochastic %D was recorded 25.84%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -52.21%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -17.56%, alongside a downfall of -51.55% for the period of the last 12 months. The shares increased approximately by -3.35% in the 7-day charts and went up by -9.13% in the period of the last 30 days. Common stock shares were lifted by -23.10% during last recorded quarter.